Article Contents ::
- 1 The Brand Name GANGUARD Has Generic Salt :: GANCICLOVIR
- 2 GANGUARD Is From Company RANBAXY (S.S.) Priced :: Rs. 2205
- 3 GANGUARD have GANCICLOVIR is comes under Sub class Anti Virals (Non Retroviral) of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Anti Virals (Non Retroviral)
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name GANGUARD Has Generic Salt :: GANCICLOVIR
GANGUARD Is From Company RANBAXY (S.S.) Priced :: Rs. 2205
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
GANCICLOVIR | CAP | Rs. 2205 | 10 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
GANGUARD | RANBAXY (S.S.) | 500MG | 10 | Rs. 2205 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From RANBAXY (S.S.) :: GANGUARD | GANCICLOVIR | Anti Infectives | Anti Virals (Non Retroviral) |
Indications for Drugs ::
CMV retinitis, Pneumonitis, Cytomegaloviral infections
Drug Dose ::
Adult: IV Cytomegaloviral infections Induction: 5 mg/kg 12 hrly for 14-21 days. Maintenance: 5 mg/kg once daily for 7 days/wk or 6 mg/kg once daily for 5 days/wk. Prevention of cytomegaloviral infections in immunocompromised patients Initial: 5 mg/kg 12 hrly for 7-14 days. Maintenance: 5 mg/kg once daily for 7 days/wk or 6 mg/kg once daily for 5 days/wk. Renal impairment: For dialysis patients: 1.25 mg/kg for induction or 0.625 mg/kg for maintenance, to be given postdialysis on days when dialysis is performed. CrCl (ml/min) 10-24 1.25 mg/kg 24 hrly for induction, then 0.625 mg/kg 24 hrly for maintenance. 25-49 2.5 mg/kg 24 hrly for induction, then 1.25 mg/kg 24 hrly for maintenance. 50-69 2.5 mg/kg 12 hrly for induction, then 2.5 mg/kg 24 hrly for maintenance. >70 5 mg/kg 12 hrly for induction, then 5 mg/kg 24 hrly for maintenance. Ophth: Cytomegaloviral retinitis As intravitreal implant which can last for 5-8 mth: Use as directed. Eye Gel: Instill 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals and then 1 drop 3 times per day for 7 days.
Contraindication ::
Hypersensitivity; absolute neutrophil count <500 cells/mm3; platelet count <25,000/mm3; pregnancy, lactation. Not to be used as a bolus inj. Drug Precautions ::
Renal impairment; preexisting cytopenias or history of cytopenic reactions to drugs; child; contraceptive precautions to be followed during and at least 90 days thereafter; care in administering only into veins with good blood flow. Avoid contact with the skin and eyes. Maintain adequate hydration during infusion. Monitor WBC and platelet counts regularly during treatment. Eye examinations should be conducted at least once every 4-6 wk during treatment for CMV retinitis.
Drug Side Effects ::
Haematolgical disturbances; marrow depression; GI disturbances; fever, rash and abnormal LFTs; irritation and phlebitis at inj site. Less frequent: CV, CNS, metabolic, musculoskeletal, respiratory, urogenital, ocular effects, cutaneous symptoms and increased serum-creatinine and BUN concentration. Potential risk of testicular effects and female fertility.
Pregnancy category ::
3
Drug Mode of Action ::
Ganciclovir is a synthetic guanine nucleoside analogue with activity against cytomegalovirus (CMV). It competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase, thus inhibiting viral DNA synthesis.
Drug Interactions ::
Increased risk of haematologic toxicity w/ zidovudine. May increase serum levels of didanosine. Increased serum concentration w/ probenecid and other drugs that inhibit renal tubular secretion and resorption. Use of IV ganciclovir w/ oral mycophenolate mofetil may result in increased plasma concentrations of both drugs due to competition for renal tubular secretion. Concomitant use w/ immunosuppressive agents (e.g. azathioprine, ciclosporin, corticosteroids) may result in excessive suppression of bone marrow or the immune system. Generalised seizure may occur when taken w/ imipenem and cilastatin. Concurrent use w/ drugs that inhibit replication of rapidly dividing cells (e.g. dapsone, pentamidine, pyrimethamine, flucytosine, cytotoxic antineoplastic agents, amphotericin B, co-trimoxazole, other nucleoside analogues) may result in additive toxicity.